Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

Fizazi K, Smith MR, Hussain M, Saad F, Sternberg CN, David Crawford E, Aragon-Ching JB, Schostak M, Tutrone R, Morgans AK, Sentana-Lledo D, Joensuu H, Mohamed AF, Littleton N, Srinivasan S, Buttkewitz Y, Li R, Kuss I, Tombal B

Year

2026

Journal

European journal of cancer (Oxford, England : 1990)